Prime Medicine (PRME) Enterprise Value (2021 - 2026)

Prime Medicine has reported Enterprise Value for 6 years, with the latest figure at -$135.5 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 3.45% year-over-year to -$135.5 million; the trailing twelve-month figure through Mar 2026 stood at -$135.5 million (up 3.45% YoY), and the FY2025 full-year result was -$177.7 million, up 4.2% from the prior year.
• Enterprise Value for Q1 2026 stood at -$135.5 million, up from -$177.7 million in the prior quarter.
• The five-year high for Enterprise Value was -$48.8 million in Q3 2023, with the low at -$286.1 million in Q4 2022.
• Historically, Enterprise Value has averaged -$151.8 million across 5 years, with a median of -$140.3 million in 2025.
• The largest YoY upside for Enterprise Value was 70.04% in 2024 against a maximum downside of 151.94% in 2024.
• Prime Medicine's Enterprise Value stood at -$286.1 million in 2022, then surged by 59.38% to -$116.2 million in 2023, then sank by 59.6% to -$185.5 million in 2024, then climbed by 4.2% to -$177.7 million in 2025, then climbed by 23.74% to -$135.5 million in 2026.
• The last three Enterprise Value figures came in at -$135.5 million (Q1 2026), -$177.7 million (Q4 2025), and -$208.4 million (Q3 2025), per Business Quant data.